Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK4/6 inhibitor: from quiescence to senescence

20 Oct 2015

Abstract excerpt

The CDK4 and CDK6 kinases (CDK4/6) are the first cyclin dependent kinases to be activated and initiate transition through G1 phase of the cell cycle. In response to mitogenic growth factors, the CDK4/6 kinase together with one of three D-type cyclins (D1, D2, D3) initiates G1 progression by virtue of its capacity to phosphorylate the retinoblastoma protein (RB), a bona fide tumor suppressor and Gate Keeper of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26697514
DOI: 10.18632/oncoscience.256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK4/6 inhibitor: from quiescence to senescencePMID 26697514Read ↗

Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer TreatmentSemantic proximity Read ↗

Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumorsSemantic proximity Read ↗

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2Semantic proximity Read ↗

Molecular Pathways: CDK4 Inhibitors for Cancer TherapySemantic proximity Read ↗

Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cellsSemantic proximity Read ↗

Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27Semantic proximity Read ↗

CDK4/6 inhibition induces a senescence-associated secretory phenotype via delayed NF-κB activation.Semantic proximity Read ↗

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNASemantic proximity Read ↗

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescenceSemantic proximity Read ↗

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.Semantic proximity Read ↗

Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast CancerSemantic proximity Read ↗

Oncogenic signals prime cancer cells for toxic cell growth during a G1 cell cycle arrestSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.